<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810316</url>
  </required_header>
  <id_info>
    <org_study_id>A6131015</org_study_id>
    <nct_id>NCT00810316</nct_id>
  </id_info>
  <brief_title>Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population</brief_title>
  <official_title>Evaluate The Pharmacokinetics Of Two Alprazolam Formulations (Immediate Release And Extended Release Tablets) And A Clonazepam Tablet In A Healthy Mexican Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the pharmacokinetics of single doses of benzodiazepines in Mexican adult healthy
      volunteers: a) alprazolam tablet extended release, b) alprazolam tablet immediate release,
      and clonazepam tablet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine pharmacokinetics of alprazolam and clonazepam in Latin-American population; in
      Mexico, both drugs are still widely used as first or second choice in the treatment of
      anxiety disorders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC last: Area under the curve of plasma concentration from administration up to time t (last sampling timepoint) calculated by trapezoid method.</measure>
    <time_frame>Sampling times: 0 to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC inf: Area under the curve of plasma concentration from administration up to infinitum extrapolated time.</measure>
    <time_frame>Sampling times: 0 to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum plasma concentration graphically obtained, based on plasma concentration versus time profile.</measure>
    <time_frame>Sampling times: 0 to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t 1/2: Half life time.</measure>
    <time_frame>Sampling times: 0 to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time from administration up to maximum plasma concentration, graphically obtained based on plasma concentration versus time profile.</measure>
    <time_frame>Sampling times: 0 to 96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>No Secondary Outcomes</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam</intervention_name>
    <description>Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>Tafil, Xanax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam XR</intervention_name>
    <description>Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Tafil AP, Xanax XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonazepam</intervention_name>
    <description>Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions</description>
    <arm_group_label>Treatment C</arm_group_label>
    <other_name>Rivotril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female volunteers aged between 18 and 40 years old.

        Exclusion Criteria:

          -  Subjects presenting changes on their vital signs constants registered at volunteers'
             screening.

          -  Volunteers with any of the following: noncompliance of proposed inclusion criteria;
             requiring another drug product throughout the study conduction; pregnant or nursing
             females; history of cardiovascular, renal, hepatic, muscular, metabolic,
             gastrointestinal, neurological, endocrine, psychiatric, hematopoietic or any other
             anemia kind, disease, asthma, or organic disorder; history of dyspepsia, gastritis,
             esophagitis, duodenal or gastric ulcer or any condition possibly affecting drug
             absorption; history of acute narrow or glaucoma; exposed to drug products known as
             hepatic enzyme or inductors; who had received any drug product within 14 days or 5
             half lives; who had been hospitalized due to any problem within 60 days prior to study
             start; history of sensitivity to BZD; who had drink alcohol or any beverage containing
             xanthines or who had taken smoked food or grapefruit juice within 72 hours prior to
             start hospitalization period, who had blood donated or lost 450 mL or more within 60
             days prior to study start; requiring any special diet regardless the cause.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Col. Arenal Tepepan</city>
        <state>Mexico D.F.</state>
        <zip>14610</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6131015&amp;StudyName=Evaluate%20Pharmacokinetics%20Of%20Two%20Different%20Pharmaceutical%20Oral%20Formulations%20Of%20Alprazolam%20And%20A%20Clonazepam%20Tablet%20In%20Mexican%20Healthy%20Populat</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2008</study_first_posted>
  <last_update_submitted>September 30, 2009</last_update_submitted>
  <last_update_submitted_qc>September 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Alprazolam</keyword>
  <keyword>Alprazolam extended release</keyword>
  <keyword>Clonazepam</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Mexican population</keyword>
  <keyword>Healthy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
    <mesh_term>Clonazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

